Humira reduces rate of uveitis flares

A study of patients with ankylosing spondylitis (AS) treated with Humira, a tumour necrosis factor alpha (TNF-alpha) blocker, has found that the drug cuts the rate of uveitis flares by approximately half.

A study of patients with ankylosing spondylitis (AS) treated with Humira, a tumour necrosis factor alpha (TNF-alpha) blocker, has found that the drug cuts the rate of uveitis flares by approximately half.

The RHAPSODY (Review of safety and effectiveness witH Adalimumab in Patients with active ankylosing spOnDYlitis) study was designed to evaluate the effectiveness of Humira as a treatment for the signs and symptoms of AS in patients with active disease despite previous non-steroidal anti-inflammatory drug (NSAID) therapy. The 1,250 patients enrolled also included a subset of patients with uveitis (n=274). Patients received 40 mg of Humira subcutaneously every other week for 12 weeks. Patients with symptomatic uveitis at baseline and/or in the previous year received the same regimen for a total of 20 weeks.

It was discovered that the rate of uveitis flares was reduced by approximately half, during Humira treatment, compared with the rate prior to the trial.

Related Videos
Noninfectious uveitis, uveitic macular oedema: A synopsis of frontline therapies
Approaches for managing treatment of patients with endophthalmitis
ARMOR study: Evaluating antibiotic resistance in the treatment of staph infections
Investigating efficacy of OC-02 to stimulate the trigeminal nerve for the treatment of dry eyes
Studying teprotumumab adherence in patients with thyroid eye disease
Corneal cross-linking and epithelial management: four pearls for success
Related Content
© 2023 MJH Life Sciences

All rights reserved.